Navigation Links
Cobalis Expects to Report Phase III Top-Line Results in May

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced it has been informed by its independent contract research organization that it would need more time to combine Cobalis' three locked data bases into a single database before un-blinding and conducting the statistical analysis required to generate top-line results for Cobalis' twin pivotal Phase III Clinical Trials of PreHistin(TM) in seasonal allergic rhinitis. The Company anticipates reporting its top-line results later in May.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. Cobalis plans to seek FDA approval to market PreHistin over-the-counter in the US. For further information, visit www.cobalis.com

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and un certainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our quarterly report on Form 10-QSB filed with the SEC on February 20, 2007.

Contact

Jaffoni & Collins Incorporated
David Collins or Steven Hecht, 212-835-8500
CLSC@jcir.com


'"/>




Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the leading ... with Hyatt Place Nashville/Downtown to deliver the best sleep ... therapy machines in over two hundred of its guest ... parts of having a great stay is sleeping well," ... Place Nashville/Downtown. "We,re pleased to be able to offer ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... compound DMT210, in a Phase 2 acne rosacea ... to downregulate the proinflammatory cytokines in the skin ... acne rosacea. This clinical trial, ...
(Date:1/18/2017)... The report " Automated Breast Ultrasound System (ABUS) Market ... End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... , Germany , UK, France , ... , China , Japan , ... Saudi Arabia , UAE, South Africa ), ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to ... Kim brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Dr. Kim to the CDG team” said President and Managing Partner Dr. Steven A. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to run ... international charity that provides free surgery to poor children suffering from cleft lip and ... I have run to support the efforts of the American Heart Association and the ...
Breaking Medicine News(10 mins):